CSL LTD SPON.ADR 2 (CSJA) - Total Liabilities
Based on the latest financial reports, CSL LTD SPON.ADR 2 (CSJA) has total liabilities worth €17.90 Billion EUR (≈ $20.93 Billion USD) as of December 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
CSL LTD SPON.ADR 2 - Total Liabilities Trend (2022–2025)
This chart illustrates how CSL LTD SPON.ADR 2's total liabilities have evolved over time, based on quarterly financial data. See how liquid is CSL LTD SPON.ADR 2's working capital to evaluate short-term liquidity relative to the company's equity base.
CSL LTD SPON.ADR 2 Competitors by Total Liabilities
The table below lists competitors of CSL LTD SPON.ADR 2 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Aselsan Elektronik Sanayi ve Ticaret AS
IS:ASELS
|
Turkey | TL120.03 Billion |
|
Haleon plc
NYSE:HLN
|
USA | $16.12 Billion |
|
Skandinaviska Enskilda Banken AB (publ)
ST:SEB-A
|
Sweden | Skr3.44 Trillion |
|
ArcelorMittal SA
AS:MT
|
Netherlands | €41.06 Billion |
|
JD.com Inc Adr
NASDAQ:JD
|
USA | $401.67 Billion |
|
Becton Dickinson and Company
NYSE:BDX
|
USA | $26.70 Billion |
|
Block, Inc
NYSE:XYZ
|
USA | $18.31 Billion |
|
ArcelorMittal SA
XETRA:ARRD
|
Germany | €41.06 Billion |
Liability Composition Analysis (2022–2025)
This chart breaks down CSL LTD SPON.ADR 2's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see CSL LTD SPON.ADR 2 (CSJA) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.86 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.96 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.47 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CSL LTD SPON.ADR 2's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CSL LTD SPON.ADR 2 (2022–2025)
The table below shows the annual total liabilities of CSL LTD SPON.ADR 2 from 2022 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | €18.00 Billion ≈ $21.04 Billion |
-3.35% |
| 2024-06-30 | €18.62 Billion ≈ $21.77 Billion |
+1.16% |
| 2023-06-30 | €18.41 Billion ≈ $21.52 Billion |
+33.70% |
| 2022-06-30 | €13.77 Billion ≈ $16.10 Billion |
-- |
About CSL LTD SPON.ADR 2
CSL Limited engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment manufactures, markets, and distributes plasma produ… Read more